23 Feb Autolus
Posted at 18:44h
in
Chris Vann, Senior Vice President and Chief Operating Officer
April 21 | 11:30am | Gaudi 3 Ballroom
London, United Kingdom
(NASDAQ: AUTL)
In-Person Presentation
Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.
